linjc16/ctgov huggingface dataset:
Cardiorenal Syndrome in End-Stage Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Cardiorenal Syndrome (CRS) is prevalent among end-stage renal disease (ESRD) patients. Recently, its prevalence is rising. There are several different clinical presentations of this syndrome. It has a high rate of morbidity and mortality. The purpose of this study is to find the connection between the heart pathology and its effect on ESRD patients. This will aid in choosing the appropriate medical therapy for these patients, and hopefully, aid in increasing their quality of life, and decrease their morbidity and mortality.

Conditions
-----------------
Cardiorenal Syndrome, Heart Disease, End-stage Renal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: End-stage renal patients Exclusion Criteria: Cancer patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dialysis Patients<br>End-stage renal disease patients undergoing dialysis at the Hillel Yaffe Medical Center. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart Pathology Identification | Visual identification of heart pathology in ESRD patients using echocardiography by measuring the ejection fraction of the left-ventricle during the systolic and diastolic phases. Valvular pathology is measured by the size of the valve. | One hour |
Quality of Life for Children With Zirconium Anteroir Crowns Versus Strip Composite Crowns

Study Overview
=================
Brief Summary
-----------------
Early Childhood Oral Health Impact Scale (ECOHIS) will be used for detection of oral health related quality of life for children using strip composite crowns versus zirconium crowns at 6 and 12 months

Official Title
-----------------
Evaliation of Oral Health Quality of Life for Children With Zirconium Crowns Versus Anteroir Strip Composite Crowns After 6 and 12 Months

Conditions
-----------------
Caries

Intervention / Treatment
-----------------
* Other: Zirconium crowns
* Other: Strip composite crowns


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy children Cariuos primary anteroir teeth Cooperative children Exclusion Criteria: children with systemic diseases Children with bad oral habits

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Strip composite crowns<br> | Other: Strip composite crowns<br>* Strip composite crowns<br>|
| Experimental: Zirconium crowns<br> | Other: Zirconium crowns<br>* Prefabricated pirmary anteroir teeth zirconium crowns<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oral health related quality of life | Early Childhood Oral Health Impact Scale (ECOHIS). | 12 months |
Comparison of Patients With and Without Foreign Body Aspiration After Bronchoscopy.

Study Overview
=================
Brief Summary
-----------------
To compare patients under 5 years of age with foreign body aspiration and without foreign body aspiration with radiological and blood gas results.

Detailed Description
-----------------
Foreign body aspiration in children is a serious cause of mortality and morbidity. It is a preventable and treatable disease. Difficulties in diagnosis arise in non-radiopaque foreign body aspirations. Recently, when there is a suspicious history, bronchoscopy is recommended. Bronchoscopy is used to both diagnose and treat foreign body aspiration. Bronchoscopy seems to continue to be performed in suspicious cases until a method to establish a definitive diagnosis of foreign body aspirations before the operation is invented. In our study, to compare patients under 5 years of age with foreign body aspiration and without foreign body aspiration with radiological and blood gas results.

Official Title
-----------------
Comparison of Symptoms and Findings and Short-term Results After Bronchoscopy in Patients With and Without the Foreign Body in Children Under 5 Years Old Who Underwent Bronchoscopy With Suspicion of Foreign Body Aspiration. A Prospective Study.

Conditions
-----------------
Foreign Body Aspiration, Blood Gas, Bronchoscopy

Intervention / Treatment
-----------------
* Device: Rigit bronchoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected foreign body aspiration Exclusion Criteria: infection, trauma

Ages Eligible for Study
-----------------
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Foreign body aspiration.<br>Patients undergoing bronchoscopy with suspicion of foreign body aspiration. There is a foreign body in the bronchoscopy performed on these patients and it is the treated group. | Device: Rigit bronchoscopy<br>* After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.<br>|
| Active Comparator: Group with no foreign body aspiration<br>Patients undergoing bronchoscopy with suspicion of foreign body aspiration, but there is no foreign body in bronchoscopy. | Device: Rigit bronchoscopy<br>* After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Foreign body aspiration | The presence of a foreign body in the airway by bronchoscopy, radiological findings, blood gas | 1 week |
TDCS in Acute Stroke

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety of transcranial direct current stimulation in aphasia therapy in acute and post-acute stroke.

Detailed Description
-----------------
TDCS has been shown to have a positive effect on clinical outcome in both motor rehabilitation and aphasia treatment in chronic aphasic patients. In healthy subjects the method sped up reaction times in naming and language learning tasks. In TDCS a weak current is applied to the subjects head increasing excitatory activity which might lead to improved brain function.

Official Title
-----------------
Safety Study of Transcranial Direct Current Stimulation in Aphasia Therapy in Acute and Post-acute Stroke

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: DKI ED2011
* Device: Sham-TDCS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first media stroke language impairment informed consent right handedness NIHSS < 20 Exclusion Criteria: previous Epilepsy oder epileptogenic events epilepsy typical elements in EEG hypersensitive skin (head) metal implants (head) pace maker or other electronic implants previous head/brain surgery medication reducing seizure threshold previous psychiatric events

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TDCS - DKI ED2011<br>TDCS with DKI ED2011 session is followed by a behavioral naming therapy with different cues | Device: DKI ED2011<br> <br> |
| Sham Comparator: Sham-TDCS<br>Sham-TDCS session is followed by a behavioral naming therapy with different cues | Device: Sham-TDCS<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skin irritation |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improved language | improved picture naming | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TDCS, STROKE, APHASIA, NAMING
Fetal Myocardial Performance Index in Diabetic Pregnancies

Study Overview
=================
Brief Summary
-----------------
The myocardial tissue is the most likely structure affected by hyperglycemia. The myocardial performance index (MPI) is a pulsed wave Doppler-derived index of global myocardial function. It is defined as the sum of the isovolumetric contraction time (ICT) and isovolumetric relaxation time (IRT) divided by the ejection time (ET) The fetal right heart contributes more to the cardiac output than the left heart; therefore, it is important to assess the right ventricular function. The investigators will measure right ventricular MPI in diabetic and normal pregnancies.

Detailed Description
-----------------
Gestational diabetes mellitus (GDM) is the most common metabolic disorder in pregnancy, with an overall prevalence of 3-7 % during pregnancy. The myocardial tissue is the most likely structure affected by hyperglycemia. The myocardial performance index (MPI) is a pulsed wave Doppler-derived index of global myocardial function. It is defined as the sum of the isovolumetric contraction time (ICT) and isovolumetric relaxation time (IRT) divided by the ejection time (ET) The fetal right heart contributes more to the cardiac output than the left heart; therefore, it is important to assess the right ventricular function. The investigators will measure right ventricular MPI in diabetic and normal pregnancies.

Official Title
-----------------
Fetal Myocardial Performance Index in Diabetic Pregnancies

Conditions
-----------------
Gestational Diabetes, Myocardial Dysfunction

Intervention / Treatment
-----------------
* Other: myocardial performance index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-40 years old pregnant women Exclusion Criteria: fetal cardiac anomalies multiple gestations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetic pregnancies<br>Pregnant women with pregestational or gestational diabetes mellitus | Other: myocardial performance index<br>* fetal right ventricular myocardial performance index measured with tissue doppler<br>|
| non-diabetic pregnancies<br>Pregnant women without pregestational or gestational diabetes mellitus | Other: myocardial performance index<br>* fetal right ventricular myocardial performance index measured with tissue doppler<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ultrasonographic myocardial performance index values | cardiac contractility will be measured with Doppler ultrasonography | during procedure |
Genomewide Screening of Pathological Myopia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the possible candidate gene of pathological myopia

Detailed Description
-----------------
High myopia (pathological myopia) is caused by excessive axial elongation that primarily involves the ora-equatorial area and the posterior pole. Peripheral fundus changes and posterior staphyloma formation are ophthalmoscopic evidences of this process. Pathological myopia often accompanied by glaucoma, cataracts, macular degeneration, and retinal detachment, leading to blindness when the damage to the retina is extremely severe. Population and family studies in Chinese have provided evidence for a genetic component to pathologic myopia. Children of myopic parents are more likely to have myopia than are children of nonmyopic parents. The ocular components (axial length, anterior chamber depth, and corneal curvature) and refractive errors of MZ twins are more closely aligned than are those of DZ twins. Therefore, it is possible to search a potential candidate gene for myopia through the genomic study of pathological myopia.

Official Title
-----------------
Genomewide Screening of Pathological Myopia

Conditions
-----------------
Pathological Myopia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: They are unrelated Chinese subjects with high myopia ≦-6.00D. The diagnosis of myopia is determined by the refractive error. Anisometropic individuals, with a refractive error of ≦-6.00 D for one eye and ≦-6.00 D for the other eye, with at least a 2-D difference between the two eyes, are considered unaffected. Exclusion Criteria: Individuals are excluded if there is known ocular disease or insult that could predispose to myopia, such as retinopathy of prematurity or early-age media opacification, or if they had a known genetic disease associated with myopia, such as Stickler or Marfan syndrome.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pathological myopia, genomic
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable disease on prior Fujisawa sponsored FK228 clinical trials.

Detailed Description
-----------------
This is a Phase II, non-randomized, open-label, single arm, continuation trial.

Official Title
-----------------
A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Have Completed a Prior Clinical Study With FK228

Conditions
-----------------
Carcinoma, Renal Cell, Prostatic Neoplasms

Intervention / Treatment
-----------------
* Drug: FK228 (romidepsin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has completed 6 cycles of therapy in a prior Fujisawa-sponsored FK228 clinical trial; Patient has immediate past participation (not to exceed 21 days from Day 15 of cycle 6 in the previous study) in a prior Fujisawa-sponsored FK228 clinical trial; Patient has demonstrated stable disease, partial response or complete response as best overall response in their prior Fujisawa-sponsored FK228 clinical trial. Exclusion Criteria: Patient has been on a prior Fujisawa-sponsored FK228 clinical trial, left the trial and then received alternative anti-neoplastic therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FK228 (romidepsin)<br>romidepsin | Drug: FK228 (romidepsin)<br>* Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.<br>* Other names: romidepsin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with adverse events |  | Up to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the effect of depsipeptide therapy on performance status as measured by the Karnofsky score assessment |  | Up to 6 months | 
| To evaluate the time to objective disease progression. |  | Up to 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FK228, Hormone Refractory Prostate Cancer
VAS Correlation With BMI

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to observe if any correlation between Body mass index and VAS values exists in patients who has gone under abdominal surgery. Group I : Patients with BMI<30 Group II: Patients with BMI between 30 and 34.9 Group III: Patients with BMI between 35 and 39.9 Group IV: Patients with BMI between 40 and 49.9 Group V : Patients with BMI >50 After the end of surgery patients will be extubated and in the recovery room morphine PCA (patient-controlled analgesia) treatment will be started according to their adjusted body weight. When VAS values over 4,10 mg/kg Paracetamol IV will be used as an escape treatment. VAS values and Delivery and Demand of the PCA and additional need for analgesics will be recorded in the first 48 hours.

Official Title
-----------------
Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial

Conditions
-----------------
Morbid Obesity

Intervention / Treatment
-----------------
* Drug: Morphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing abdominal surgery and who will be given PCA treatment for postoperative pain. Exclusion Criteria: patients younger than 18 years old, patients with uncompensated diabetes or related polyneuropathy, patients receiving antidepressants or have a diagnosis of depression

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group 5<br>Patients with BMI > 50 | Drug: Morphine<br> <br> |
| Active Comparator: Group IV<br>Patients with BMI between 40 and 49.9 | Drug: Morphine<br> <br> |
| Active Comparator: Group III<br>Patients with BMI between 35 and 39.9 | Drug: Morphine<br> <br> |
| Active Comparator: Group II<br>patients with BMI between 30 and 34.9 | Drug: Morphine<br> <br> |
| Active Comparator: Group I<br>Patients with BMI <30 | Drug: Morphine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Scores on the Visual Analog Scale | Correlation between the VAS Scores and BMI will evaluated | 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
morbid obesity, postoperative pain
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine the applicability and utility of Gerd Q in the diagnosis of GERD and in the assessment of treatment response.

Official Title
-----------------
Diagnosis and Response to Treatment Using a Reliable Gerd Questionnaire-an In Clinical Practise Study

Conditions
-----------------
Gastroesophageal Reflux Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of either gender aged between 18-79 years of age Patients must be having symptoms of gastroesophageal reflux disease Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the applicability and utility of Gerd Q in the diagnosis of GERD and assessment of treatment response |  | The applicability and utility of the Gerd Questionnaire will be done on 2 vists- Day 1 and Day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess and monitor the treatment response of patients diagnosed with GERD |  | The monitoring and assessment of treatment response using the Gerd Questionnaire will be done on 2 vists-Day 1 and Day 30 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gerd Questionnaire